

Attorney Docket No. P003 C5

hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to	: Mail Stop
Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	

Dated: 8-30-04

Signature: Aboy Bergullo

(Abby Berghella)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	John F. Shanley			
Serial No.:	10/824,124	Art Unit:	3731	
Filed:	April 13, 2004	Examiner:	Unassigned	
For:	EXPANDABLE MEDICAL DEVICE WITH S-SHAPED BRIDGING ELEMENTS			

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

•	* *	examination of the application.
1.	Enclos	ures accompanying this Information Disclosure Statement are:
	la.	A PTO-Form 1449 listing all patents, publications, applications, or other information submitted for consideration by the office.
	1b.	A legible copy of:
		☐ Each publication or that portion which caused it to be listed on the PTO-1449;
		For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
		all other information or portion which caused it to be listed on the PTO-1449.

2.	⊠	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
		Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
		☑ Before the mailing of the first Office action on the merits;
		☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
	3a.	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
	3b.	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
		enclosed
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:
		enclosed.
	The C	Certification Statement in Item 5 below is applicable.
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not <b>received</b> by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
5.	⊠	This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No., filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
	6c.	
7.		This is a Supplemental Information Disclosure Statement.
	7a.	This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8.		In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
	8a.	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
	8b.	set forth in the application.
	8c.	enclosed as an attachment hereto.
9.		The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Conor Medsystems, Inc. Deposit Account No. 50-3100.

10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Date: August 30, 2004

Cindy A. Lynch

Respectfully submitted

Reg. No. 38,699

Conor Medsystems, Inc. 1003 Hamilton Court Menlo Park, CA 94025

(650) 614-4100

Page	_1_	of	2

Substitute for forms 1449A/PTO & 1449B/PTO	Attorney's Dkt. No.	Application No.
	P003 C5	10/824,124
FIRE INFORMATION DISCLOSURE	Applicant	
FIRST INFORMATION DISCLOSURE  MSTATEMENT BY APPLICANT  STATEMENT BY APPLICANT	Shanley	
1 2000 STILIVILIAI DI VILLIOVIAI	Filing Date	Group
\$\$\tag{\$\psi\$}	4-13-04	3731

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (mm-dd-yyyy)
	US-20010125803		Vallana et al.	07-03-03
	US-20020007209		De Scheerder et al.	01-17-02
	US-20040122505		Shanley	06-24-04
	US-20040127976		Diaz	07-01-04
	US-20040127977		Shanley	07-01-04
	US-20040144506		Shanley et al.	06-24-04
	US-5104404		Wolff	
	US-5695516		Fischell et al.	
	US-6033433		Ehr et al.	
	US-6254632		Wu et al.	
	US-6334870		Ehr et al.	
	US-6461380		Сох	
	US-6660034		Mandrusov et al.	
	US-6706061		Fischell et al.	
	US-6716240		Fischell et al.	·
	US-6723119		Pinchasik et al.	
	US-6730116		Wolinsky et al.	
	US-D480809		Seibold et al.	
	US-D481130		Seibold et al.	
	US-D481139	-	Seibold et al.	

Examiner		Date	
Initials	· ·	Considered	

Page 2 of 2

•		
Substitute for forms 1449A/PTO & 1449B/PTO	Attorney's Dkt. No.	Application No.
	P003 C5	10/824,124
FIRST INFORMATION DISCLOSURE	Applicant	
STATEMENT BY APPLICANT	Shanley	
	Filing Date	Group
SEP 1 0 2004 &	4-13-04	3731

PATEMIA TRADE		FOREIGN PA	TENT DOCUMEN	ITS		
Examiner Initials	Document Number	Kind Code (if known)	Country	Publication Date (mm-dd-yyyy)	Translatio	on No
	EP-0979059		EP	03-10-04		
	EP-1172074		EP	01-16-02		
	EP-1222941		EP	07-17-02		
100.00	WO-0226281		PCT	4-4-02		
	WO-9916386		PCT	4-8-99		

Examiner	Date	
Initials		
miliais	Considered	